Literature DB >> 3009109

Survival and prognostic indicators in compensated and decompensated cirrhosis.

G D'Amico, A Morabito, L Pagliaro, E Marubini.   

Abstract

Six-year survival of cirrhosis was assessed in a series of 1155 consecutive patients (751 men, 404 women). Among the men, 33% were alcoholics and 18% were HBsAg positive; corresponding figures for the women were 15% and 6% respectively. Features of decompensation at first presentation were observed in 63% of the patients. Six-year survival was 54% in compensated and 21% in decompensated patients. No significant differences in survival were found between alcoholics and nonalcoholics. Leading causes of death were liver failure (49%), hepatocellular carcinoma (22%), and bleeding (13%). The prognostic role of 21 variables was evaluated separately in compensated and decompensated patients by the Cox's regression model. The following variables were found to be significant predictors of death risk in compensated patients: male sex, HBsAg positivity, age, prothrombin time prolongation, and esophageal varices. In decompensated disease the significant indicators of death risk were: hepatocellular carcinoma, encephalopathy, hemorrhage, SGOT, esophageal varices, gamma globulins, prothrombin time prolongation, continued abuse of alcohol, HBsAg positivity, gamma glutamyl transpeptidase, and cholinesterase. A simple prognostic index based upon the relative risk coefficient of the significant variables is suggested.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009109     DOI: 10.1007/bf01320309

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  The natural history of cirrhosis. I. Survival with esophageal varices.

Authors:  A J GARCEAU; T C CHALMERS
Journal:  N Engl J Med       Date:  1963-02-28       Impact factor: 91.245

2.  Effect of prednisone on the survival of patients with cirrhosis of the liver. A report from the Copenhagen Study Group for Liver Diseases.

Authors: 
Journal:  Lancet       Date:  1969-01-18       Impact factor: 79.321

3.  Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease.

Authors:  W J Powell; G Klatskin
Journal:  Am J Med       Date:  1968-03       Impact factor: 4.965

4.  The morphology of cirrhosis: definition, nomenclature, and classification.

Authors:  P P Anthony; K G Ishak; N C Nayak; H E Poulsen; P J Scheuer; L H Sobin
Journal:  Bull World Health Organ       Date:  1977       Impact factor: 9.408

5.  Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial.

Authors:  L Pagliaro; F Rinaldi; A Craxì; S Di Piazza; G Filippazzo; G Gatto; G Genova; S Magrin; A Maringhini; S Orsini; U Palazzo; M Spinello; M Vinci
Journal:  Dig Dis Sci       Date:  1983-01       Impact factor: 3.199

6.  Prognostic factors in cirrhosis identified by Cox's regression model.

Authors:  P Schlichting; E Christensen; P K Andersen; L Fauerholdt; E Juhl; H Poulsen; N Tygstrup
Journal:  Hepatology       Date:  1983 Nov-Dec       Impact factor: 17.425

7.  Continued heavy drinking and survival in alcoholic cirrhotics.

Authors:  S A Borowsky; S Strome; E Lott
Journal:  Gastroenterology       Date:  1981-06       Impact factor: 22.682

8.  Good news for drinkers--or is it?

Authors:  T B Reynolds
Journal:  Gastroenterology       Date:  1978-01       Impact factor: 22.682

9.  A 20-year prospective study of cirrhosis.

Authors:  J B Saunders; J R Walters; A P Davies; A Paton
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-24
  9 in total
  109 in total

Review 1.  Cirrhosis of liver.

Authors:  B S Anand
Journal:  West J Med       Date:  1999-08

2.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

3.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

4.  The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis.

Authors:  Jung Won Jeon; Hyun Phil Shin; Joung Il Lee; Kwang Ro Joo; Kwan Mi Pack; Jae Myung Cha; Jae Jun Park; Jun Uk Lim; Kyuseong Lim
Journal:  Surg Endosc       Date:  2012-05-31       Impact factor: 4.584

5.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

6.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.

Authors:  L Benvegnù; M Gios; S Boccato; A Alberti
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Prognosis and life expectancy in chronic liver disease.

Authors:  A Propst; T Propst; G Zangerl; D Ofner; G Judmaier; W Vogel
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

Review 8.  Pathophysiology and management of pediatric ascites.

Authors:  Mahmoud Sabri; Miguel Saps; John M Peters
Journal:  Curr Gastroenterol Rep       Date:  2003-06

9.  Comparison of liver biopsy and transient elastography based on clinical relevance.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Erik Goto; Takahisa Sato; Takamasa Ohki; Tadashi Goto; Hideo Yoshida; Fumihiko Kanai; Yosuke Sugioka; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

10.  Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma.

Authors:  Keiichiro Yoneyama; Yuka Nebashi; Yuji Kiuchi; Minoru Shibata; Keiji Mitamura
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.